Eduovisual
Female Reproductive & Breast
Cervical cancer screening: ASCCP guidelines
— ~14,000 new invasive cases and ~4,000 deaths annually; incidence has fallen ~75% since cytology screening began
— Median age at diagnosis ~50; peak dysplasia detection in women 25–35
— >95% of cases driven by persistent high-risk HPV (hrHPV) infection, especially types 16 and 18 (~70% of cancers)
— Step 3 tests when to screen, when to stop, and what to do with abnormal results in primary care
— Decisions hinge on age, prior screening history, immune status, and risk factors — not symptoms
— Cervical cancer is largely asymptomatic until advanced; screening is the entire game
— HPV acquisition → transient infection (90% clear in 1–2 yr) → persistent infection → CIN 1/2/3 → invasive carcinoma over 10–20 years
— This long latency is why screening intervals can safely be 3–5 years
— Postcoital bleeding, intermenstrual bleeding, malodorous discharge, pelvic pain
— Friable cervical mass on exam → biopsy directly, do not Pap a visible lesion and call it negative
— Early sexual debut, multiple partners, smoking, immunosuppression (HIV, transplant, chronic steroids), prior CIN, in-utero DES exposure, inadequate prior screening
— >50% of cervical cancers occur in unscreened or under-screened women — the highest-yield prevention intervention is bringing non-adherent patients into screening
Board pearl: A visible cervical lesion or unexplained postcoital bleeding mandates colposcopy with biopsy, not a repeat Pap — cytology can be falsely negative in frankly invasive disease due to necrosis and inflammation obscuring malignant cells.
— Step 3 vignettes typically open: "32-year-old woman presents for routine well-woman exam..." — your job is to know the screening algorithm cold
— Less commonly: abnormal bleeding pattern prompts evaluation that uncovers dysplasia
— Age — dictates which screening modality is allowed (cytology alone, co-test, or primary hrHPV)
— Date and result of last Pap, HPV test, colposcopy, or excisional procedure — drives ASCCP risk-based algorithm
— HPV vaccination status — does NOT change screening intervals currently, but is documented
— Immunosuppression: HIV (CD4 count), solid organ transplant, SLE on immunosuppressants, IBD on biologics — these patients screen differently and start earlier (age 21 regardless of sexual debut, or within 1 year of sexual activity)
— Pregnancy status — alters management of abnormal results (defer treatment, never do ECC)
— Hysterectomy history: was the cervix removed? Was the indication benign or CIN2+?
— Smoking is the most modifiable cofactor — accelerates progression and impairs clearance
— DES exposure in utero (now rare, mothers born <1971) → clear cell adenocarcinoma risk
— Abnormal uterine bleeding, postcoital bleeding, persistent watery/bloody discharge, deep dyspareunia, pelvic/back pain, leg edema (advanced disease with lymphatic obstruction)
Step 3 management: When a vignette gives you a Pap result, before choosing next step, mentally extract: patient age, cytology result, HPV result, prior abnormal history, and immune status. ASCCP 2019 guidelines are risk-based — the same Pap result can warrant different actions depending on the 5-year CIN3+ risk derived from these inputs.
— External genitalia: inspect for condyloma, lichen sclerosus, vulvar lesions (separate cancer risk)
— Speculum exam: visualize the entire cervix, note the transformation zone (TZ) — squamocolumnar junction where dysplasia originates
— Pap sampling: rotate broom/spatula+brush 360°, sample ectocervix and endocervix to capture TZ
— Bimanual: uterine size, adnexal masses, cervical motion tenderness, parametrial nodularity (concerning for advanced spread)
— Friable, bleeding, exophytic, or ulcerated cervical lesion — biopsy this directly, do not just Pap
— Barrel-shaped cervix → endocervical adenocarcinoma
— Fixed cervix on bimanual or rectovaginal exam → parametrial extension
— Hydronephrosis on imaging → ureteral compression → stage IIIB minimum
— Report should state presence of endocervical/TZ component
— Absent TZ component in a routine screen with otherwise normal cytology and negative HPV → still acceptable, no early repeat needed
— Unsatisfactory specimen → repeat in 2–4 months
— Spraying lubricant on the speculum can interfere with liquid-based cytology — use water or minimal water-based lube
— Sampling during heavy menses reduces interpretability
— In postmenopausal women with atrophy, atypical cells may reflect atrophy rather than dysplasia — a course of vaginal estrogen before repeat cytology can clarify
Key distinction: A visible cervical lesion is a biopsy indication, not a Pap indication. Cytology screens populations; biopsy diagnoses lesions. Vignettes describing a "friable mass" with a recent normal Pap are testing whether you'll fall for false reassurance.
— Cytology (Pap) alone every 3 years — ages 21–65
— Primary hrHPV testing every 5 years — ages 25–65 (ACS preferred; FDA-approved platforms only)
— Co-test (cytology + hrHPV) every 5 years — ages 30–65
— <21 years: do NOT screen, regardless of sexual activity (HPV clears spontaneously; treatment harms exceed benefit)
— 21–24: cytology alone every 3 years; manage minor abnormalities conservatively
— 25–29 (ACS) or 30–29 transitional: cytology q3y, or primary HPV q5y where available
— 30–65: any of three strategies; co-test or primary HPV preferred per ACS
— >65: discontinue if adequate prior screening (3 consecutive negative cytologies OR 2 consecutive negative co-tests within 10 yr, most recent within 5 yr) AND no CIN2+ in past 25 yr
— Women >65 without documented screening should continue screening until criteria met — age alone is not a stop signal
— Total hysterectomy for benign indication + no history of CIN2+ → stop screening entirely (no vaginal cuff Paps)
— Supracervical (cervix retained) → continue per age
— Hysterectomy for CIN2+ or cancer → continue vaginal cuff cytology for 25 years after the index lesion
Board pearl: The single most tested cutoff is age 21 to start, age 65 to stop with adequate prior screening. Starting "at sexual debut" or screening teens is a wrong answer — it produces overdiagnosis of transient HPV without mortality benefit, and harms from overtreatment include cervical incompetence and preterm birth.
— Acetic acid (3–5%) applied → dysplastic epithelium turns acetowhite
— Lugol's iodine → normal glycogenated squamous epithelium stains brown; dysplasia is iodine-negative (yellow)
— Vascular patterns concerning for high-grade lesion: mosaicism, punctation, atypical vessels
— Directed biopsies of all acetowhite/abnormal areas; endocervical curettage (ECC) to sample the canal — contraindicated in pregnancy
— Adequate: entire TZ visualized and lesion margins seen
— Inadequate: TZ not fully visualized (common postmenopausal or post-treatment) → diagnostic excision (LEEP/cone) often needed
— Positive HPV 16 or 18 carries higher CIN3+ risk than other hrHPV types and lowers the threshold for immediate colposcopy in many algorithms
— HPV 16+ with negative cytology → colposcopy
— HPV 18+ with negative cytology → colposcopy
— Other hrHPV+ with negative cytology → repeat co-test in 1 year (or colposcopy if 5-year CIN3+ risk ≥4%)
— CIN 1: low-grade, mostly regresses
— CIN 2: ambiguous — p16 staining helps; treat or observe based on age and fertility
— CIN 3 / carcinoma in situ: high-grade, treat
— AIS (adenocarcinoma in situ): glandular, harder to detect, treat aggressively (cold knife cone preferred)
— NILM, ASC-US, ASC-H, LSIL, HSIL, AGC, squamous cell carcinoma, adenocarcinoma
Step 3 management: ASC-US + HPV negative is reassuring — return to routine screening (5-year interval with co-test). ASC-US + HPV positive → colposcopy. LSIL, HSIL, ASC-H, AGC → colposcopy regardless of HPV status. AGC additionally needs endometrial sampling if ≥35 or risk factors for endometrial cancer.
— Old algorithms keyed off the current Pap/HPV result alone
— New algorithms use 5-year CIN3+ risk calculated from current result + prior history
— Thresholds for action:
— ≥4% immediate risk → colposcopy
— <4% immediate, ≥0.55% 5-year → surveillance (1-year or 3-year)
— <0.15% 5-year → return to routine 5-year screening
— ≥60% immediate CIN3+ risk → expedited treatment (LEEP without colposcopy biopsy) is an option in non-pregnant patients ≥25
— Same screening result + worse history (prior HSIL, prior CIN3, HPV persistence) = higher risk = more aggressive action
— Same result + clean history = less aggressive action
— 1-year follow-up with HPV-based testing is the most common surveillance interval
— Two consecutive negative annual tests → return to routine 5-year screening
— Persistent hrHPV at two timepoints is the strongest single risk factor for CIN3+
— A single positive HPV with negative cytology in a low-risk patient usually warrants 1-year repeat, not immediate colposcopy (unless 16/18+)
— Acceptable for HSIL cytology with HPV 16+ and prior negative screening history meeting risk threshold
— Not acceptable in pregnancy, age <25, or when future fertility is a major concern — prefer colposcopic confirmation first
Board pearl: When a Step 3 question gives you a confusing combination of Pap/HPV/history, the safe-and-correct middle ground is usually "repeat co-test in 1 year" for low-grade abnormalities and "colposcopy" for any high-grade cytology (HSIL, ASC-H, AGC) or any HPV 16/18 positivity regardless of cytology.
— If persistent HPV+ or any cytologic abnormality at 1 year → colposcopy
— Ages 25+: reflex HPV testing preferred
— HPV negative → repeat co-test in 3 years (essentially routine)
— HPV positive → colposcopy
— Ages 21–24: repeat cytology in 1 year (do not reflex HPV — high HPV prevalence, low cancer risk)
— Ages 25+ with HPV+ (or unknown HPV) → colposcopy
— Ages 25+ with HPV negative → repeat co-test in 1 year (preferred) or colposcopy
— Ages 21–24 → repeat cytology in 1 year
— Ages 25+ → colposcopy or expedited LEEP (especially if HPV 16+)
— Ages 21–24 → colposcopy only (no expedited treatment — fertility preservation)
— AGC has higher cancer risk than ASC-US and includes endometrial pathology in the differential
Step 3 management: The 21–24 age group is the trap. Even with LSIL or ASC-US + HPV+, the answer is usually repeat cytology in 1 year, not colposcopy. Aggressive workup in this age group causes more harm (preterm birth from excisional procedures) than benefit.
— Preceded by low-grade cytology (ASC-US/LSIL): observe with HPV-based testing in 1 year — most regress
— Preceded by high-grade cytology (HSIL/ASC-H): higher occult disease risk — diagnostic excision or close surveillance with repeat colpo at 1 year
— Persistent CIN1 ≥2 years: treat or continue surveillance per patient preference
— Age <25 or fertility-priority: observe with colposcopy + HPV testing q6–12 months for up to 2 years (regression rate ~40%)
— Age ≥25 or persistent CIN2: treat (excision or ablation)
— CIN 2 in pregnancy: observe, repeat postpartum — never treat antepartum
— Treat all (except pregnancy → defer until postpartum)
— Excisional preferred over ablative when adequate colposcopy and no suspicion of invasion
— Cold knife cone (CKC) preferred over LEEP — better margin assessment; multifocal "skip" lesions common
— Hysterectomy after childbearing complete
— LEEP (loop electrosurgical excision): outpatient, local anesthesia, gold standard for CIN2/3
— Cold knife cone: operating room, preferred for AIS or microinvasion concern (no thermal artifact at margin)
— Ablation (cryotherapy, laser): only if biopsy-proven, adequate colposcopy, no AIS/cancer suspicion, lesion fully visualized
— Positive endocervical margin on LEEP → higher recurrence risk, surveillance HPV testing at 6 months
— Bleeding, infection, cervical stenosis, cervical insufficiency → preterm birth and PPROM in subsequent pregnancies
— Cumulative excision depth correlates with preterm risk
CCS pearl: After LEEP for CIN2+, order HPV-based testing at 6 months, then annually until 3 consecutive negatives, then every 3 years for at least 25 years — even past age 65. Post-treatment surveillance does not stop at 65.
— Discontinue screening if criteria met: 3 consecutive negative cytologies OR 2 consecutive negative co-tests within 10 years, most recent within 5 years, AND no CIN2+ within 25 years
— Discontinuation is permanent — do not restart for new sexual partner alone in average-risk women
— ~20% of new cervical cancer cases occur in this group
— Continue screening until criteria for discontinuation are met
— Co-testing or primary HPV testing is reasonable; cytology alone is acceptable
— Continue surveillance for 25 years after the index lesion, even if it carries them past 65 or 75
— Annual or 3-yearly HPV testing depending on time since treatment
— Atrophy mimics ASC-US; vaginal estrogen for 4–6 weeks then repeat cytology is acceptable to clarify
— Cervical stenosis after menopause complicates sampling and colposcopy — may need diagnostic excision for adequate evaluation
— Screening cessation is appropriate when life expectancy <10 years regardless of age — invasive cervical cancer takes a decade+ to develop and progress
— Document shared decision-making
— No direct effect on screening intervals
— Renal/liver transplant patients are immunosuppressed → annual screening indefinitely, like HIV patients
Step 3 management: A 68-year-old with three negative Paps in her 50s–60s presents for "routine" screening — the correct answer is no further screening, document discontinuation criteria met, address other preventive care (bone density, lipids, colon cancer). Reflexively ordering another Pap is a wrong answer.
— Screening continues on routine schedule if due
— Abnormal results: colposcopy is safe; biopsy of suspicious lesions is safe; ECC and endometrial sampling are CONTRAINDICATED
— CIN2/3 in pregnancy → observe with colposcopy each trimester; reassess 6 weeks postpartum
— Treatment (LEEP/cone) only if invasive cancer suspected — significant pregnancy loss risk
— Mode of delivery determined by obstetric indications, not CIN
— Do not screen — high HPV prevalence (clears spontaneously), near-zero cancer incidence, high harm from overtreatment
— Even with sexual debut, HIV-negative status, this rule holds for the immunocompetent
— Begin screening at age 21 OR within 1 year of sexual activity if onset before 21
— Cytology annually for 3 years, then every 3 years if all negative — lifelong screening, no upper age cutoff
— Co-testing acceptable after age 30
— Lower threshold for colposcopy; manage abnormalities more aggressively
— Total hysterectomy for benign indication, no CIN2+ history → stop
— Subtotal (cervix retained) → continue per age
— Hysterectomy for CIN2+/cancer → vaginal cuff cytology for 25 years
— Annual screening with cytology of cervix AND upper vagina, indefinite — clear cell adenocarcinoma risk
Board pearl: "HIV-positive 19-year-old, sexually active since 16" → start screening now with annual cytology. The immunocompromised exception breaks the age-21 rule.
— Overdiagnosis: detection of CIN1 that would have regressed → unnecessary anxiety, procedures
— Overtreatment of CIN1/CIN2 in young women → cervical insufficiency, preterm birth (2-fold), PPROM, low birth weight
— False reassurance from inadequate or poorly performed Pap
— Anxiety from HPV-positive result without cancer
— LEEP/cone: bleeding (5–10%), infection, cervical stenosis (1–5%), cervical insufficiency (depth-dependent), dysmenorrhea, hematometra from stenosis
— Repeated excisions multiply preterm birth risk — counsel before second procedure
— Anesthesia-related complications with cold knife cone
— Local extension: parametrial invasion, bladder/rectum involvement (fistulas), ureteral obstruction → hydronephrosis and obstructive uropathy (stage IIIB)
— Hemorrhage from friable tumor — vaginal packing, embolization, radiation hemostasis
— Lymphedema of lower extremities from pelvic node involvement or post-radiation
— Metastases: para-aortic nodes, lungs, liver, bone
— Radiation cystitis, proctitis, vaginal stenosis, ovarian failure (premature menopause), secondary malignancy
— Cisplatin: nephrotoxicity, neuropathy, ototoxicity
— HPV diagnosis: stigma, partner relationship strain — counsel that HPV is ubiquitous (~80% lifetime prevalence) and a positive test does not imply infidelity
Key distinction: Cervical insufficiency from prior LEEP causes painless second-trimester pregnancy loss — different from cervical stenosis (causes hematometra/dysmenorrhea). Both are procedure complications but present opposite ways. A young woman planning pregnancy with CIN2 may reasonably observe rather than treat to preserve cervical length.
— Any HSIL, ASC-H, AGC, or AIS cytology
— ASC-US or LSIL with positive hrHPV (age ≥25)
— Persistent hrHPV at 1 year
— HPV 16 or 18 positive regardless of cytology (age ≥25)
— Visible cervical lesion (refer for direct biopsy, not Pap)
— Postcoital bleeding or unexplained abnormal uterine bleeding
— Biopsy-proven invasive cervical cancer (any stage)
— AIS (adenocarcinoma in situ) — surgical management considerations
— Suspicion of microinvasion on excisional specimen
— Recurrent CIN3 after two excisional procedures
— AGC favor neoplasia
— Most screening, colposcopy, and LEEP are outpatient
— Cold knife cone, radical hysterectomy, chemoradiation planning → inpatient or specialized outpatient surgical centers
— Massive vaginal hemorrhage from cervical mass → admit, type and cross, vaginal packing, urgent radiation oncology consult for hemostatic radiation, IR for embolization
— Obstructive uropathy with AKI → percutaneous nephrostomy or ureteral stenting; admit for renal recovery
— Sepsis from pyometra or post-procedure infection → admit, broad-spectrum antibiotics, imaging
— Suspected vesicovaginal or rectovaginal fistula → urology/colorectal surgery consultation
— Gyn-onc, radiation oncology, medical oncology, palliative care, fertility-sparing consultations for early-stage disease in reproductive-age patients
CCS pearl: In a CCS case with a woman who has stage IIIB cervical cancer and AKI from bilateral hydronephrosis, the right move is urgent urinary diversion (percutaneous nephrostomy) before initiating cisplatin-based chemoradiation — cisplatin is nephrotoxic and requires adequate renal function.
— Chlamydia, gonorrhea, trichomonas, HSV — friable, inflamed cervix that may mimic neoplasia
— Pap may show reactive/inflammatory changes; treat infection and reassess
— NAAT testing for GC/CT in any woman with cervicitis findings <25 or with risk factors
— Endocervical polyps: benign, may cause postcoital bleeding
— Remove and send for pathology to exclude underlying malignancy
— Columnar epithelium on ectocervix, common in young/pregnant women, OCP users
— Appears red and friable but is normal; no treatment needed
— AGC cytology has higher likelihood of endometrial than cervical pathology in women ≥35
— Workup: colposcopy + ECC + endometrial biopsy
— HPV-related, same risk factors; co-occur in 5–10% of patients with cervical dysplasia
— Inspect entire lower genital tract at colposcopy
Key distinction: Cervical ectropion vs. cervical cancer — both can appear red and bleed with contact. Ectropion is symmetric around the os, has a smooth surface, and is asymptomatic in a young woman or OCP user. Cancer is friable, irregular, exophytic, ulcerated, or indurated and warrants biopsy.
— Cervicitis (infectious — STI workup)
— Cervical polyp
— Cervical ectropion
— Atrophic vaginitis (postmenopausal)
— Vaginal trauma
— Endometrial pathology (polyp, hyperplasia, cancer)
— Polyp, Adenomyosis, Leiomyoma, Malignancy/hyperplasia
— Coagulopathy, Ovulatory dysfunction, Endometrial, Iatrogenic (anticoagulants, hormonal contraception), Not yet classified
— Endometrial cancer until proven otherwise — transvaginal ultrasound (endometrial stripe >4 mm) or endometrial biopsy
— Atrophy is most common benign cause but is a diagnosis of exclusion
— PID, endometriosis, ovarian pathology, IBS, interstitial cystitis, musculoskeletal
— BV, candidiasis, trichomoniasis, atrophic vaginitis, retained foreign body, fistula
— Do NOT stop at the Pap — investigate further with pelvic exam, STI testing, transvaginal ultrasound, endometrial biopsy if age ≥45 or risk factors
— Cytology has false-negative rate for invasive cancer; visible lesion or persistent symptoms → biopsy
Board pearl: A normal Pap does NOT rule out cervical or endometrial cancer in a symptomatic patient. Pap is a screening test for asymptomatic populations. Symptomatic patients require directed evaluation: speculum exam for visible lesions, transvaginal ultrasound, endometrial biopsy as indicated by age and risk.
— Covers HPV 6, 11, 16, 18, 31, 33, 45, 52, 58
— Routine age 11–12 (can start at 9); catch-up through age 26
— Shared decision-making for ages 27–45 (less benefit, but possible for newly at-risk adults)
— Dosing: 2 doses (0, 6–12 mo) if started before age 15; 3 doses (0, 1–2, 6 mo) if started at 15 or older or immunocompromised
— Safe in lactation; defer in pregnancy but no harm documented if given inadvertently
— Reduces incidence of cervical, vulvar, vaginal, anal, oropharyngeal cancers and genital warts
— HPV-based testing at 6 months post-procedure, then annually until 3 consecutive negatives
— Then every 3 years for at least 25 years total post-treatment
— Continue beyond age 65 if within the 25-year window
— Smoking accelerates HPV progression and impairs clearance — counsel at every visit
— Pharmacotherapy: varenicline, bupropion, NRT
— Condoms reduce but do not eliminate HPV transmission
— Partner does not require testing (no validated male HPV screening test); partner vaccination may benefit
— Pelvic exam + cytology of vaginal cuff every 3–6 months for 2 years, then 6–12 months for years 3–5, then annually
— Imaging only if symptomatic
— Manage radiation menopause: HRT generally safe (squamous cervical cancer is non-hormonal); vaginal dilators for stenosis; lymphedema management
Step 3 management: HPV vaccine + cervical cancer screening are complementary, not substitutes. A vaccinated 30-year-old still screens on the standard schedule — vaccination covers ~90% of cancer-causing HPV, not 100%, and screening also detects non-HPV-driven disease.
— Cytology alone: every 3 years
— Co-test (≥30): every 5 years
— Primary HPV (≥25): every 5 years
— Surveillance HPV testing at 1 year for most low-grade scenarios
— Two consecutive negatives → return to routine 5-year screening
— HPV-based testing at 6 months, then annually × 3 negatives, then every 3 years for 25 years minimum
— Margin status (positive endocervical margin) increases recurrence risk → closer monitoring
— HPV is common and usually clears — a positive test is not a diagnosis of cancer or recent infidelity
— Cervical cancer takes 10–20 years to develop — there is time to evaluate and act, but follow-through matters
— Adherence to follow-up is the single most important determinant of outcome after an abnormal result — track and recall patients
— At age 65 with criteria met: document explicitly in the chart, communicate to patient, redirect to other preventive priorities (DEXA, lipids, colon, lung if eligible)
— HEDIS cervical cancer screening measure: % of women 24–64 with documented screening per guidelines — drives clinic-level outreach
— When transferring care, obtain prior cytology, HPV, colposcopy, and pathology records before deciding next screening interval — risk-based algorithms require this history
— Patients who "lose" their records often get re-started from scratch — counsel them to maintain a personal screening record
Board pearl: A patient who misses follow-up after an abnormal Pap is at higher risk of cancer than one who never screened — because she has a documented lesion progressing unaddressed. Active patient outreach and recall systems are a Step 3 patient safety expectation, not optional.
— Many patients do not realize HPV testing is being done — informed consent and pre-test counseling about the implications of a positive result (sexual transmission, partner discussion, anxiety) are recommended
— Particularly important for adolescents and patients with limited health literacy
— In many states, minors can consent to STI testing and reproductive care without parental notification
— HPV vaccine consent rules vary by state — know local law
— Billing/EOB disclosure to parents can inadvertently breach confidentiality — flag the chart and use confidentiality protections
— Failure to track and notify abnormal Pap results is a leading source of malpractice claims in primary care
— Implement closed-loop notification: every abnormal result must be communicated, acknowledged, and acted upon with documented next steps
— EHR-based reminder systems and registries reduce loss to follow-up
— When patients change clinicians, abnormal results pending or surveillance schedules are commonly dropped
— Always reconcile pending screening/surveillance at new-patient visits and at hospital discharge
— Suspected sexual abuse in a minor during pelvic exam findings → mandatory child protective services report
— Confirmed STIs (gonorrhea, chlamydia, syphilis, HIV) → public health reporting per state
— Older patients may be uncomfortable stopping screening; explain rationale, document discussion
— Most cervical cancer deaths occur in under-screened populations — uninsured, rural, racial/ethnic minorities, immigrants
— Federal programs (NBCCEDP) provide free screening; refer eligible patients
— Acceptable when CIN3+ risk ≥60%; requires explicit consent regarding fertility implications — overtreatment of false-positives is real
Step 3 management: A patient whose abnormal Pap result was never communicated and now presents 4 years later with invasive cancer represents a system failure. The correct action: full disclosure to the patient, root-cause analysis, implementation of closed-loop result notification — not blame the patient for missing follow-up.
Board pearl: When the vignette gives age, Pap result, HPV result, and a brief history, organize your decision: age cutoff → cytology grade → HPV result/genotype → prior history → match to the ASCCP risk threshold. This systematic approach prevents pattern-matching errors.
— "18-year-old sexually active for 2 years presents for first Pap"
— Correct answer: No screening indicated until age 21; provide HPV vaccination, STI screening, contraception counseling
— "67-year-old with three negative Paps in her 50s and 60s"
— Correct answer: Discontinue screening, document adequate prior negative screening
— "30-year-old, ASC-US on Pap, HPV negative"
— Correct answer: Return to routine screening (co-test in 3 years) — not 1-year follow-up
— "22-year-old with LSIL on first Pap"
— Correct answer: Repeat cytology in 1 year — not colposcopy, not HPV reflex
— "20-year-old HIV-positive woman, sexually active"
— Correct answer: Begin screening now with annual cytology
— "26-year-old at 18 weeks gestation, HSIL on Pap"
— Correct answer: Colposcopy with biopsy (no ECC, no treatment unless invasion); reassess postpartum
— "45-year-old with postcoital bleeding and friable cervical mass; recent Pap normal"
— Correct answer: Biopsy the lesion directly — do not repeat Pap
— "55-year-old s/p TAH-BSO for fibroids, no CIN history, presents for Pap"
— Correct answer: No further cervical/vaginal cytology indicated
— "42-year-old, AGC on Pap"
— Correct answer: Colposcopy + ECC + endometrial biopsy
— "34-year-old, NILM cytology, HPV 16 positive"
— Correct answer: Colposcopy (HPV 16/18 positivity is a colposcopy indication regardless of cytology)
— "29-year-old s/p LEEP for CIN3 six months ago"
— Correct answer: HPV-based testing now, then annually until 3 negatives, then q3y for 25 years
Key distinction: Recognize the trap of "do something" answers in young patients. In ages 21–24 with low-grade abnormalities, "repeat in 1 year" is usually correct, and "colposcopy now" is the distractor designed to punish over-aggressive management.
Cervical cancer screening is a risk-based, age-stratified preventive intervention: start cytology at age 21, integrate hrHPV testing from age 25–30, screen every 3–5 years per modality, manage abnormal results by ASCCP 2019 risk thresholds, treat CIN2/3 with LEEP (except in pregnancy and young women preserving fertility), and stop at age 65 only with adequate prior negative screening.
Board pearl: When in doubt on a Step 3 cervical screening question, anchor on patient age, cytology grade, HPV status, prior history, and immune status — the right answer almost always falls out of this five-variable assessment matched against the ASCCP risk thresholds.